UROGEN PHARMA LTD (URGN)

UroGen Pharma Stock Earns 91 RS Rating

UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier.

UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants

UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

PRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing...

Noteworthy Thursday Option Activity: AIG, URGN, X

UroGen Catapults On 'Unprecedented' Results For Gel-Based Cancer Drug

The company is working on a treatment for non-muscle invasive bladder cancer.

UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024

UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

UroGen Pharma Appoints David Lin as New Chief Commercial Officer

UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit

Notable Monday Option Activity: ALGM, URGN, NEXT

URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q1 2024

URGN stock results show that UroGen Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips UroGen Pharma (NASDAQ:URGN) just reported results for the first quarter of 2024...

UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights

UroGen Pharma to Participate at Upcoming Investor Conferences

New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy

UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024

New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial

UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024

UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers

UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Commit To Purchase UroGen Pharma At $10, Earn 20.3% Annualized Using Options

UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals

URGN Makes Notable Cross Below Critical Moving Average

URGN Stock Earnings: UroGen Pharma Misses EPS, Beats Revenue for Q4 2023

URGN stock results show that UroGen Pharma missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.

URGN Stock Earnings: UroGen Pharma Misses EPS, Beats Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips UroGen Pharma (NASDAQ:URGN) just reported results for the fourth quarter of 202...

UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024

UroGen stock falls as Teva seeks Jelmyto generic (NASDAQ:URGN)

Shares of UroGen Pharma (URGN) fell after Teva Pharma (TEVA) filed for FDA approval of a generic version of URGN's bladder cancer therapy, Jelmyto. Read more here.

UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference

UroGen Pharma to Participate at Upcoming Investor Conferences

UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102